Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BSX

BSX - Boston Scientific Corp Stock Price, Fair Value and News

$93.79+0.18 (+0.19%)
Market Closed

53/100

BSX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

BSX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$85.02

Target 3M

$90.57

Target 6M

$88.72

BSX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BSX Price Action

Last 7 days

2.3%

Last 30 days

-2.1%

Last 90 days

-6.7%

Trailing 12 Months

-8.3%

BSX RSI Chart

BSX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BSX Valuation

Market Cap

139.0B

Price/Earnings (Trailing)

49.93

Price/Sales (Trailing)

7.19

EV/EBITDA

30.02

Price/Free Cashflow

36.36

BSX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$85.02

Target 3M

$90.57

Target 6M

$88.72

BSX Fundamentals

BSX Revenue

Revenue (TTM)

19.4B

Rev. Growth (Yr)

20.34%

Rev. Growth (Qtr)

0.08%

BSX Earnings

Earnings (TTM)

2.8B

Earnings Growth (Yr)

61.32%

Earnings Growth (Qtr)

-5.03%

BSX Profitability

EBT Margin

16.90%

Return on Equity

11.9%

Return on Assets

6.52%

Free Cashflow Yield

2.75%

BSX Investor Care

Shares Dilution (1Y)

0.58%

Diluted EPS (TTM)

1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202517.6B18.5B19.4B0
202414.7B15.2B15.9B16.7B
202313.0B13.4B13.8B14.2B
202212.2B12.3B12.6B12.7B
202110.1B11.2B11.5B11.9B
202010.8B10.2B10.1B9.9B
20199.9B10.1B10.4B10.7B
20189.3B9.5B9.7B9.8B
20178.6B8.7B8.8B9.0B
20167.7B8.0B8.2B8.4B
20157.4B7.3B7.4B7.5B
20147.2B7.2B7.3B7.4B
20137.1B7.1B7.1B7.1B
20127.6B7.4B7.3B7.2B
20117.8B7.8B7.8B7.6B
20100007.8B
Get all data in R, Python etc through our Historical Stock Data APIs

About Boston Scientific Corp

BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEbostonscientific.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES45000

Boston Scientific Corp Frequently Asked Questions

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Boston Scientific Corp is 139.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BSX's fair value in chart for subscribers.

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

As of Wed Jan 28 2026, BSX's PE ratio (Price to Earnings) is 49.93 and Price to Sales (PS) ratio is 7.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Boston Scientific Corp has provided 0.183 (multiply by 100 for percentage) rate of return.